Accountable Care Organization

ACO Name and Location

Inspira Care Connect, LLC
165 Bridgeton Pike
Mullica Hill, New Jersey 08062


ACO Primary Contact

Primary Contact Name

April Venable

Primary Contact Phone Number

(856) 641-6275

Primary Contact Email Address

VenableA@ihn.org


Organizational Information

ACO participants:

ACO Participants

ACO Participant in Joint Venture (Enter Y or N)

The Martin Jay Kessler Medical Services, LLC

N

Edward Melman

N

Robert Patitucci

N

South Cumberland Medical Associates Pc

N

Inspira Health Network Medical Group, P.C.

N

Inspira Medical Centers, Inc.

N

Underwood-Memorial Hospital

N

Pine Street Family Practice

N

Jack M Shields, MD.

N

Arthur Starr & Sherry Lench PTR

N

Satish K. Mittal

N

Eyexam Associates PA

N

Diering And Dipietro Associates Ptrs

N

Cumberland Internal Medicine

N

Wasser & Edelstein PA

N

Family Practice Associates Of Cumberland Co Pc

N

Cumberland Nephrology Associates

N

Gubman Eye Associates

N

Kaplan & Tyson, Llc Dba Eye Associates

N

South jersey Radiation Oncology, P.C.

N

Lyons And Chvala Nephrology Assoc.

N

Elite Eyecare Associates PC

N

Medical Group Associates Llc

N

Town Vision Associates LLC

N

Premier Eye Associates LLC

N

Medical Alliance of Southern New Jersey, PC

N

DePersia, Chernoff & Ocasio, PC.

N

Cumberland Family Medicine, LLC

N

Ct Holdings Medical Group Llc

N


ACO governing body:

Member

Member's Voting Power

Membership Type

ACO Participant TIN Legal Business Name/DBA, if Applicable

Last Name

First Name

Title/Position

DiAngelo

John

Member

1

ACO Particiant Representative

Inspira Medical Centers, Inc.

Kohli

Alka

Member

1

ACO Particiant Representative

Inspira Medical Centers, Inc.

Trotz

Chris

Member

1

ACO Particiant Representative

CT Holdings Medical Group LLC

Shields

Jack

Member

1

ACO Particiant Representative

Jack M Shields, MD.

Ballas

Christopher

Member

1

ACO Particiant Representative

South Cumberland Medical Associates PC

Love

Sally

Member

1

ACO Medicare Beneficiary Representative

Not Applicable


Key ACO clinical and administrative leadership:

April Venable

ACO Executive

Gregory Herman

Medical Director

Joseph Piccolo

Compliance Officer

Paul Lambrecht

Quality Assurance/Improvement Officer



Associated committees and committee leadership:

Committee Name

Committee Leader Name and Position

Clinical Consensus Committee

Dr. Chris Trotz, Chair

Finance Committee

Thomas Baldosaro, Chair

Compliance Committee

Joseph Piccolo, Chair




 Types of ACO participants, or combinations of participants, that formed the ACO:

  • Partnerships or joint venture arrangements between hospitals and ACO professionals

  • Hospital employing ACO professionals


Shared Savings and Losses

Amount of Shared Savings/Losses

  • First Agreement Period

    • Performance Year 2016, $0

    • Performance Year 2015, $0

Shared Savings Distribution

  • First Agreement Period

    • Performance Year 2016

      • Proportion invested in infrastructure: N/A

      • Proportion invested in redesigned care processes/resources: N/A

      • Proportion of distribution to ACO participants: N/A

    • Performance Year 2015

      • Proportion invested in infrastructure: N/A

      • Proportion invested in redesigned care processes/resources: N/A

      • Proportion of distribution to ACO participants: N/A


Quality Performance Results

2016 Quality Performance Results:

ACO#

Measure Name

Rate

ACO Mean

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

81.66

80.51

ACO-2

CAHPS: How Well Your Providers Communicate

94.55

93.01

ACO-3

CAHPS: Patients’ Rating of Provider

93.97

92.25

ACO-4

CAHPS: Access to Specialists

85.71

83.49

ACO-5

CAHPS: Health Promotion and Education

61.05

60.32

ACO-6

CAHPS: Shared Decision Making

77.64

75.40

ACO-7

CAHPS: Health Status/Functional Status

72.19

72.30

ACO-34

CAHPS: Stewardship of Patient Resources

30.20

26.97

ACO-8

Risk Standardized, All Condition Readmission

14.93

14.70

ACO-35

Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM)

18.92

18.17

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes

58.55

53.20

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure

73.12

75.23

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

61.43

59.81

ACO-9

Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

16.88

9.27

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)

23.29

14.53

ACO-11

Percent of PCPs who Successfully Meet Meaningful Use Requirements

89.47

82.72

ACO-39

Documentation of Current Medications in the Medical Record

86.76

87.54

ACO-13

Falls: Screening for Future Fall Risk

67.27

64.04

ACO-14

Preventive Care and Screening: Influenza Immunization

68.21

68.32

ACO-15

Pneumonia Vaccination Status for Older Adults

70.49

69.21

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up

74.46

74.45

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

94.08

90.98

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

43.25

53.63

ACO-19

Colorectal Cancer Screening

55.12

61.52

ACO-20

Breast Cancer Screening

46.38

67.61

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

90.08

76.79

ACO-42

Statin therapy for the Prevention and Treatment of Cardiovascular Disease

79.18

77.72

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

23.92

18.24

ACO-41

Diabetes: Eye Exam  

27.19

44.94

ACO-28

Hypertension (HTN): Controlling High Blood Pressure

75.00

70.69

ACO-30

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

93.14

85.05

ACO-31

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

81.00

88.67

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

81.77

79.67


Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.


Note: In the Quality Performance Results file(s) above, search for “Inspira Care Connect, LLC” to view the quality performance results. This ACO can also be found by using the ACO ID A93114 in the public use files on data.cms.gov.


Payment Rule Waivers

  • No, our ACO does not use the SNF 3-Day Rule Waiver.